Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

14 results
Filters applied: . Clear all
Page 1
Global hepatitis C elimination: an investment framework.
Pedrana A, Howell J, Scott N, Schroeder S, Kuschel C, Lazarus JV, Atun R, Baptista-Leite R, 't Hoen E, Hutchinson SJ, Aufegger L, Peck R, Sohn AH, Swan T, Thursz M, Lesi O, Sharma M, Thwaites J, Wilson DP, Hellard M. Pedrana A, et al. Lancet Gastroenterol Hepatol. 2020 Jul 27:S2468-1253(20)30010-8. doi: 10.1016/S2468-1253(20)30010-8. Online ahead of print. Lancet Gastroenterol Hepatol. 2020. PMID: 32730786 Review.
Do the most heavily burdened countries have the right policies to eliminate viral hepatitis B and C?
Palayew A, Razavi H, Hutchinson SJ, Cooke GS, Lazarus JV. Palayew A, et al. Lancet Gastroenterol Hepatol. 2020 Jul 27:S2468-1253(20)30011-X. doi: 10.1016/S2468-1253(20)30011-X. Online ahead of print. Lancet Gastroenterol Hepatol. 2020. PMID: 32730784 Review.
A model of the economic benefits of global hepatitis C elimination: an investment case.
Scott N, Kuschel C, Pedrana A, Schroeder S, Howell J, Thompson A, Wilson DP, Hellard M. Scott N, et al. Lancet Gastroenterol Hepatol. 2020 Jul 27:S2468-1253(20)30008-X. doi: 10.1016/S2468-1253(20)30008-X. Online ahead of print. Lancet Gastroenterol Hepatol. 2020. PMID: 32730785 Review.
Outcomes of donor-derived superinfection screening in HIV-positive to HIV-positive kidney and liver transplantation: a multicentre, prospective, observational study.
Bonny TS, Kirby C, Martens C, Rose R, Desai N, Seisa M, Petropoulos C, Florman S, Friedman-Moraco RJ, Turgeon NA, Brown D, Segev DL, Durand CM, Tobian AAR, Redd AD. Bonny TS, et al. Lancet HIV. 2020 Jul 27:S2352-3018(20)30200-9. doi: 10.1016/S2352-3018(20)30200-9. Online ahead of print. Lancet HIV. 2020. PMID: 32730756
Pulmonary vascular resistance and clinical outcomes in patients with pulmonary hypertension: a retrospective cohort study.
Maron BA, Brittan EL, Hess E, Waldo SW, Barón AE, Huang S, Goldstein RH, Assad T, Wertheim BM, Alba GA, Leopold JA, Olschewski H, Galiè N, Simonneau G, Kovacs G, Tedford RJ, Humbert M, Choudhary G. Maron BA, et al. Lancet Respir Med. 2020 Jul 27:S2213-2600(20)30317-9. doi: 10.1016/S2213-2600(20)30317-9. Online ahead of print. Lancet Respir Med. 2020. PMID: 32730752
Efficacy and safety of osilodrostat in patients with Cushing's disease (LINC 3): a multicentre phase III study with a doubleblind, randomised withdrawal phase.
Pivonello R, Fleseriu M, Newell-Price J, Bertagna X, Findling J, Shimatsu A, Gu F, Auchus R, Leelawattana R, Lee EJ, Kim JH, Lacroix A, Laplanche A, O'Connell P, Tauchmanova L, Pedroncelli AM, Biller BMK; LINC 3 investigators. Pivonello R, et al. Lancet Diabetes Endocrinol. 2020 Jul 27:S2213-8587(20)30240-0. doi: 10.1016/S2213-8587(20)30240-0. Online ahead of print. Lancet Diabetes Endocrinol. 2020. PMID: 32730798
The impact of COVID-19 on hepatitis elimination.
Wingrove C, Ferrier L, James C, Wang S. Wingrove C, et al. Lancet Gastroenterol Hepatol. 2020 Jul 27:S2468-1253(20)30238-7. doi: 10.1016/S2468-1253(20)30238-7. Online ahead of print. Lancet Gastroenterol Hepatol. 2020. PMID: 32730783 Free PMC article. No abstract available.
Gift horse or Trojan horse?
Hilton RM. Hilton RM. Lancet HIV. 2020 Jul 27:S2352-3018(20)30193-4. doi: 10.1016/S2352-3018(20)30193-4. Online ahead of print. Lancet HIV. 2020. PMID: 32730757 No abstract available.
Eliminating viral hepatitis in the COVID-19 era: weighing challenge and opportunity.
The Lancet Gastroenterology Hepatology. The Lancet Gastroenterology Hepatology. Lancet Gastroenterol Hepatol. 2020 Jul 27:S2468-1253(20)30237-5. doi: 10.1016/S2468-1253(20)30237-5. Online ahead of print. Lancet Gastroenterol Hepatol. 2020. PMID: 32730787 Free PMC article. No abstract available.
14 results
Jump to page
Feedback